Closing In On An Artificial Pancreas
This article was originally published in Start Up
Executive Summary
Medtronic may be the front-runner in the race to market, but a number of medtech start-ups hope investors will find merit in their innovative technologies. Profiles of Beta-O2, Defymed, and Pancreum.
You may also be interested in...
Medtronic Launches Predictive MiniMed 640G Insulin Pump Outside The U.S.
The company touts the system as its latest breakthrough toward the development of an artificial pancreas. It can automatically suspend or resume insulin delivery based on pre-set thresholds.
Defymed Inc.
Defymed Inc.’s MAILPAN (MAcro-encapsulation of PANcreatic Islets) is a bioartificial pancreas that can use a broader pool of cell types while protecting the cells from rejection by the immune system.
Pancreum LLC
Pancreum LLC is creating a wearable artificial pancreas that includes two pumps and a continuous glucose monitor. The company’s plan is to continue with development and seek regulatory approval in stages that mirror the device’s unique modular configuration.